Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Cardio-Oncology

Fig. 1

From: Cardiotoxicity risk factors with immune checkpoint inhibitors

Fig. 1

Percentage of adverse cardiac event (atrial fibrillation with rapid ventricular response, heart failure with preserved/reduced ejection fraction, myocarditis, pericarditis, ventricular fibrillation/tachycardia) out of respective study population treated with immune checkpoint inhibitors. Total population for each category: African American (AA) Male 35, AA Female 22, Caucasian (Cau) Male 299, Cau Female 169. Fisher’s Exact P = 0.057 between AA and Cau male and P = 0.176 between AA and Cau females

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us